<DOC>
	<DOCNO>NCT01066052</DOCNO>
	<brief_summary>This study conduct evaluate efficacy safety recombinant human growth hormone ( r-hGH ) treatment young girl Turner Syndrome .</brief_summary>
	<brief_title>Growth Hormone Treatment Prevention Short Stature Young Girls With Turner Syndrome Before Age 4 Years</brief_title>
	<detailed_description>The study start interventional clinical trial . Following primary completion trial , sponsor together investigator decide interesting perform observational follow patient , participate interventional part study , order retrieve outcome result safety information cohort young turner patient treatment start age 4 . The follow period perform end GH treatment decide treat physician accord usual clinical practice . More recently , agree also collect information final adult height weight patient lose follow .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Turner Syndrome</mesh_term>
	<mesh_term>Gonadal Dysgenesis</mesh_term>
	<mesh_term>Primary Ovarian Insufficiency</mesh_term>
	<mesh_term>Dwarfism</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Young girl turner syndrome prove caryotype Age &lt; 4 year old GH secretion confirm ornithin stimulation test Normal glucidic metabolism confirm assessment glycosylated haemoglobin ( HbA1c ) None associate severe pathology could impact growth ( i.e . renal insufficiency , decompensated heart failure ) No previous associate treatment anabolic sexual steroid Known parental height Signed informed consent Severe associate pathology impact growth Concomitant treatment impact growth Previous associate treatment anabolic steroid Associated GH deficiency</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>4 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Growth hormone</keyword>
	<keyword>Turner syndrome</keyword>
	<keyword>r-hGH</keyword>
	<keyword>early treatment</keyword>
</DOC>